Covered recipient · General Payments record
CYNTHIA A RUTLEDGE
Allopathic & Osteopathic Physicians Family Medicine
General Payments · PY2018–2024
$4,227.47
- Reported across 257 records
- CMS publication 2026-01-23
Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.
How these totals are calculated
- The total is the sum of the General Payments records CMS published for the labeled program year(s), exactly as published. Nothing is estimated, weighted, or combined across categories.
- General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
- Featured-page threshold (a presentation gate, not a judgment): records>=3 OR total>=100 (all years).
- Methodology & Data — sourcing, labeling, and limitations.
By nature of payment
PY2024 · sorted by reported total
| Nature of payment | Amount | Records |
|---|---|---|
| Food and Beverage | $302.96 | 16 |
By paying entity
PY2024 · sorted by reported total
| Paying entity | Amount | Records |
|---|---|---|
| Novo Nordisk AS | $77.65 | 5 |
| ABBVIE INC. | $58.49 | 3 |
| PFIZER INC. | $44.50 | 2 |
| Abbott Laboratories | $29.88 | 1 |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.28 | 1 |
| IDORSIA PHARMACEUTICALS US INC | $19.90 | 1 |
| Lundbeck LLC | $16.84 | 1 |
| Acerta Pharma LLC | $16.19 | 1 |
| GlaxoSmithKline, LLC. | $15.23 | 1 |
By program year
All program years on this page · sorted by year
Payment records · PY2024 (16)
Sorted by paying entity, then date · as published by CMS
| Paying entity | Amount | Date | Nature of payment | Dispute status | Published | Record ID | Source |
|---|---|---|---|---|---|---|---|
| Abbott Laboratories | $29.88 | 10/09/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1124809009 | CMS |
| ABBVIE INC. | $18.96 | 01/16/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105991626 | CMS |
| ABBVIE INC. | $18.98 | 01/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105991628 | CMS |
| ABBVIE INC. | $20.55 | 01/25/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1105991630 | CMS |
| AstraZeneca Pharmaceuticals LP | $16.19 | 10/10/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1104308940 | CMS |
| Boehringer Ingelheim Pharmaceuticals, Inc. | $24.28 | 09/04/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1117847937 | CMS |
| GlaxoSmithKline, LLC. | $15.23 | 05/07/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1116085193 | CMS |
| IDORSIA PHARMACEUTICALS US INC | $19.90 | 08/01/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1146788639 | CMS |
| Lundbeck LLC | $16.84 | 04/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1145963622 | CMS |
| Novo Nordisk Inc | $16.45 | 01/03/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096918344 | CMS |
| Novo Nordisk Inc | $13.56 | 01/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096918524 | CMS |
| Novo Nordisk Inc | $14.79 | 05/14/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1097201832 | CMS |
| Novo Nordisk Inc | $13.82 | 05/21/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096722771 | CMS |
| Novo Nordisk Inc | $19.03 | 11/06/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1096648155 | CMS |
| PFIZER INC. | $27.46 | 09/18/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131946744 | CMS |
| PFIZER INC. | $17.04 | 12/11/2024 | Food and Beverage | Undisputed | 01/23/2026 | 1131404477 | CMS |
Source & provenance
- Dataset
- CMS Open Payments — General Payments
- Publisher of source data
- Centers for Medicare & Medicaid Services
- CMS publication date
- 2026-01-23
- Program years on this page
- 2018, 2019, 2020, 2021, 2022, 2023, 2024
- Source files
- Dataset page · Bulk file · PY2018 , PY2019 , PY2020 , PY2021 , PY2022 , PY2023 , PY2024
- Generated from
- OP_DTL_GNRL_PGYR2024_P01232026_01102026.csv
One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.
Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.